Literature DB >> 31119574

Potential false-positive urine Legionella enzyme immunoassay test results.

James Como1,2, Matthew A Moffa3,4, Nitin Bhanot3,4, Zaw Min3,4, Kelly Stefano Cole5, James Kuzyck5, Thomas L Walsh3,4.   

Abstract

The objective of this study was to identify potential false-positive urine Legionella pneumophila (Legionella) enzyme immunoassay test results. A total of 107 consecutive patients with positive EIA tests were retrospectively analyzed over a 34-month period. Concurrent blood, urine, and sputum cultures, as well as chest radiographic findings, were reviewed in these patients. Twenty patients (19%) had no radiographic evidence of pulmonary disease despite a positive EIA test. In those 20 patients, 14 also had growth of non-Legionella bacteria. Of patients with an infiltrate or opacity on chest imaging, only 27 had Legionella sputum cultures obtained, with Legionella culture growth occurring in 7 (26%). Nine other patients had negative Legionella sputum cultures but the growth of another pathogenic organism in blood, sputum, and/or urine cultures. Pseudomonas aeruginosa was the most common organism isolated, found in 20% of patients in the entire cohort. Twenty-five patients (23%) were characterized as having probable false-positive Legionella urinary antigen EIA testing, and an additional 17 patients (16%) were characterized as having possible false-positive Legionella EIA tests. Our findings suggest that urine Legionella EIA tests may lead to a substantial number of cases being misdiagnosed as Legionaries' disease in patients with non-Legionella bacterial colonization or infection.

Entities:  

Keywords:  EIA; Enzyme immunoassay; Legionella; Urine alone; Urine antigen testing

Mesh:

Substances:

Year:  2019        PMID: 31119574     DOI: 10.1007/s10096-019-03575-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  5 in total

Review 1.  Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies.

Authors:  Julio A Ramirez; Daniel M Musher; Scott E Evans; Charles Dela Cruz; Kristina A Crothers; Chadi A Hage; Stefano Aliberti; Antonio Anzueto; Francisco Arancibia; Forest Arnold; Elie Azoulay; Francesco Blasi; Jose Bordon; Steven Burdette; Bin Cao; Rodrigo Cavallazzi; James Chalmers; Patrick Charles; Jean Chastre; Yann-Erick Claessens; Nathan Dean; Xavier Duval; Muriel Fartoukh; Charles Feldman; Thomas File; Filipe Froes; Stephen Furmanek; Martin Gnoni; Gustavo Lopardo; Carlos Luna; Takaya Maruyama; Rosario Menendez; Mark Metersky; Donna Mildvan; Eric Mortensen; Michael S Niederman; Mathias Pletz; Jordi Rello; Marcos I Restrepo; Yuichiro Shindo; Antoni Torres; Grant Waterer; Brandon Webb; Tobias Welte; Martin Witzenrath; Richard Wunderink
Journal:  Chest       Date:  2020-06-16       Impact factor: 9.410

Review 2.  Legionnaires' Disease: Update on Diagnosis and Treatment.

Authors:  Diego Viasus; Valeria Gaia; Carolina Manzur-Barbur; Jordi Carratalà
Journal:  Infect Dis Ther       Date:  2022-05-03

3.  Correlation between Sputum Bacterial Culture Positive Rate and Drug Sensitivity Test Results and Disease Severity inInpatients and Its Clinical Significance: A SystematicReview and Meta-Analysis.

Authors:  Wenjing Zhou; Jing Li
Journal:  Comput Intell Neurosci       Date:  2022-07-14

4.  Campylobacter jejuni-Associated Hemophagocytic Lymphohistiocytosis and Guillain-Barre Syndrome: A Case Report.

Authors:  Fang-E Shi; Mei-Fang Chen; Yong-Jie Li; Gui-Ying Dong; Ji-Hong Zhu
Journal:  Front Med (Lausanne)       Date:  2022-07-07

5.  A community-acquired Legionnaires' disease outbreak caused by Legionella pneumophila serogroup 2: an uncommon event, Italy, August to October 2018.

Authors:  Maria Scaturro; Maria Cristina Rota; Maria Grazia Caporali; Antonietta Girolamo; Michele Magoni; Daria Barberis; Chiara Romano; Danilo Cereda; Maria Gramegna; Antonio Piro; Silvia Corbellini; Cinzia Giagulli; Giovanni Rezza; Arnaldo Caruso; Maria Luisa Ricci
Journal:  Euro Surveill       Date:  2021-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.